X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
Details:
Zepzelca (lurbinectedin) is a DNA-negative allosteric modulator. It is approved for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Zepzelca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: PharmaMar
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
Zepzelca (lurbinectedin) inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor.
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Zepzelca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2023
Details:
Zepzelca (lurbinectedin) is an alkylating drug that binds guanine residues within DNA. This triggers a cascade of events that can affect the activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in disruption of cell cycle.
Lead Product(s): Lurbinectedin,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Zepzelca
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: PharmaMar
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
Cosela (trilaciclib), an IV-administered transient CDK4/6 inhibitor, is a first-in-class therapy designed to preserve bone marrow and immune system function during chemotherapy to improve patient outcomes.
Lead Product(s): Trilaciclib,Lurbinectedin
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
Zepzelca (lurbinectedin) is a DNA-negative allosteric modulator. It is approved for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Zepzelca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: PharmaMar
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2022
Details:
Zepzelca (lurbinectedin), is an alkylating drug that binds guanine residues within DNA, triggers a cascade of events that can affect the activity of DNA binding proteins, and DNA repair pathways, resulting in disruption of cell cycle and eventual cell death.
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Zepzelca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
CDK12 inhibitor demonstrates strong anti-tumor activity as single agent and in combination with a DNA damaging agent and a PARP inhibitor in models of breast, lung, and ovarian cancer.
Lead Product(s): SY-5609,Olaparib,Lurbinectedin
Therapeutic Area: Oncology Product Name: SY-5609
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
Zepzelca (lurbinectedin), is an alkylating drug that binds guanine residues within DNA, triggers a cascade of events that can affect activity of DNA binding proteins, including some transcription factors resulting in disruption of cell cycle and eventual cell death.
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Zepzelca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
Details:
Eczacıbaşı will pursue the marketing authorization in Turkey and will have the right to commercialize the Zepzelca (Lurbinectedin), on an exclusive basis, upon approval. Lurbinectedin was granted accelerated approval by FDA for relapsed metastatic Small Cell Lung Cancer.
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Zepzelca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eczacıbaşı Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 22, 2021
Details:
Zepzelca (lurbinectedin) is a DNA-negative allosteric modulator. It is being developed for the treatment of patients with relapsed small cell lung cancer.
Lead Product(s): Lurbinectedin,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: Zepzelca
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jazz Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2021
Details:
Zepzelca (lurbinectedin) is a DNA-negative allosteric modulator. It is approved for the treatment of adult patients with stage III metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Zepzelca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: PharmaMar
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2021
Details:
ZEPZELCA® (lurbinectedin) is an alkylating drug that binds guanine residues within DNA. This triggers cascade of events that can affect activity of DNA binding proteins, including some transcription factors to treat 2L metastatic small cell lung cancer.
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Zepzelca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: PharmaMar
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2021
Details:
ZEPZELCA® (lurbinectedin) is the first new therapy approved to treat second-line metastatic SCLC in Australia in more than 20 years. ZEPZELCA approval granted under a provisional regulatory pathway.
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Zepzelca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: PharmaMar
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2021
Details:
The collaboration will provide SU2C-funded researchers access to two Jazz molecules and funds to support one or more research projects over three years. One of the projects would help explore clinical use of lurbinectedin in rare and hard to treat pediatric solid tumors.
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Zepzelca
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Stand Up To Cancer
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 10, 2021
Details:
Research findings to be presented include new data on Zepzelca® (lurbinectedin), Vyxeos®/Vyxeos® Liposomal (daunorubicin and cytarabine), also known as JZP351 (formerly known as CPX-351), and Defitelio® (defibrotide sodium).
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Zepzelca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2021
Details:
The study did not meet the pre-specified criteria of significance for the primary endpoint of overall survival (OS) in the intent-to-treat (ITT) population comparing lurbinectedin in combination with doxorubicin to the control arm.
Lead Product(s): Lurbinectedin,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Zepzelca
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: PharmaMar
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
PharmaMar and Jazz Pharma have entered into an amended and restated license agreement of the US lurbinectedin license agreement signed in December 2019 for the purpose of granting Jazz an exclusive license for Zepzelca™ (lurbinectedin) in Canada.
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Zepzelca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jazz Pharmaceuticals
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 15, 2020
Details:
This filing is based on data from the phase II monotherapy basket trial with lurbinectedin for the treatment of SCLC. lurbinectedin demonstrated an Overall Response Rate (ORR) of 35 percent and a median Duration of Response (DoR) of 5.3 month.
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: PM1183
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
Details:
Zepzelca (lurbinectedin) is a DNA-negative allosteric modulator. It is approved for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Zepzelca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: PharmaMar
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
Details:
Lurbinectedin has received priority review under the FDA's accelerated approval pathway. Data from a key Phase 2 study of the drug Lurbinectedin demonstrated a clinically meaningful advantage over current standard of care in patients in second-line SCLC therapy.
Lead Product(s): Lurbinectedin,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2020
Details:
This new agreement will allow lurbinectedin to reach the Israeli market, if approved, in the hands of one of the leading companies in the field of oncology in this country.
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Megapharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 11, 2020
Details:
Immedica gets an exclusive distribution and marketing right of the anti-tumor drug lurbinectedin for territories that include the UK, Ireland, the Nordic countries, Middle East and North Africa.
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Immedica Pharma AB
Deal Size: Undisclosed Upfront Cash: $2.1 million
Deal Type: Agreement April 29, 2020
Details:
PharmaMar submitted the NDA to FDA in December 2019 based on data from the Phase II monotherapy basket trial, which included evaluation of lurbinectedin for the treatment of relapsed SCLC.
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2020
Details:
PharmaMar & Jazz signed an exclusive license agreement for U.S. rights to lurbinectedin, the effectiveness of which was subject to the expiration or early termination of the applicable HSR waiting period.
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jazz Pharmaceuticals
Deal Size: $1,000.0 million Upfront Cash: $200.0 million
Deal Type: Licensing Agreement January 22, 2020
Details:
PharmaMar to start a Phase I-II study to determine the recommended dose and efficacy of lurbinectedin in combination with atezolizumab in patients with advanced Small Cell Lung Cancer (SCLC).
Lead Product(s): Lurbinectedin,Atezolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
